681 related articles for article (PubMed ID: 33150566)
1. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.
Ken-Opurum J; Srinivas SSS; Jain D; Shah T; Samnaliev M; Dex T; Charland S; Revel A; Preblick R
Diabetes Ther; 2023 Dec; 14(12):2109-2125. PubMed ID: 37801225
[TBL] [Abstract][Full Text] [Related]
3. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH
F1000Res; 2023; 12():914. PubMed ID: 38125558
[TBL] [Abstract][Full Text] [Related]
4. The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.
Gu S; Gu J; Wang X; Wang X; Li L; Gu H; Xu B
Health Econ Rev; 2024 Apr; 14(1):26. PubMed ID: 38564113
[TBL] [Abstract][Full Text] [Related]
5. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
Zhang X; McAdam Marx C
J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
[No Abstract] [Full Text] [Related]
6. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
Swift C; Frazer MS; Gronroos NN; Sargent A; Leszko M; Buysman E; Alvarez S; Dunn TJ; Noone J; Guevarra M
Diabetes Ther; 2024 Jul; 15(7):1547-1559. PubMed ID: 38722496
[TBL] [Abstract][Full Text] [Related]
8. The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes.
Rasmussen MF
Diabetol Int; 2020 Apr; 11(2):76-86. PubMed ID: 32206477
[TBL] [Abstract][Full Text] [Related]
9. Advances in GLP-1 treatment: focus on oral semaglutide.
Eliaschewitz FG; Canani LH
Diabetol Metab Syndr; 2021 Sep; 13(1):99. PubMed ID: 34526121
[TBL] [Abstract][Full Text] [Related]
10. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
Mezquita Raya P; Pérez A; Ramírez de Arellano A; Briones T; Hunt B; Valentine WJ
Diabetes Ther; 2013 Dec; 4(2):417-30. PubMed ID: 24132613
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.
Zhang L; Hua Z; Fang Z; Wei J; Lin Y
J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38874130
[TBL] [Abstract][Full Text] [Related]
12. Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.
Hardin M; Adanse F; Schexnayder C; Malveaux J; Agbahiwe S
Fed Pract; 2023 Dec; 40(Suppl 6):S24-S30. PubMed ID: 38812588
[TBL] [Abstract][Full Text] [Related]
13. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
14. Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse.
Vashisht R; Jung K; Shah N
AMIA Annu Symp Proc; 2016; 2016():2036-2042. PubMed ID: 28269963
[TBL] [Abstract][Full Text] [Related]
15. Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System
Palacios A; Rodriguez-Cairoli F; Balan D; Rojas-Roque C; Moreno-López C; Braun B; Augustovski F; Pichon-Riviere A; Bardach A
Appl Health Econ Health Policy; 2023 Jul; 21(4):637-650. PubMed ID: 37062046
[TBL] [Abstract][Full Text] [Related]
16. Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia.
AlRuthia Y; Hani Aburisheh K; Ata S; Bin Salleeh R; Alqudhibi SB; Alqudhibi RB; Alkraidis Z; Humood Alkhalaf H; Abdullah Almogirah A; Mujammami M; Al Khalifah R
Saudi Pharm J; 2024 May; 32(5):102057. PubMed ID: 38601976
[TBL] [Abstract][Full Text] [Related]
17. Willingness to Pay (WTP) for Newer Treatment Options for Diabetes: A Study Among Patients at a Tertiary Care Centre.
Vaidya S; Atal S; Joshi R
Cureus; 2024 Mar; 16(3):e56103. PubMed ID: 38618372
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control.
Seinfeld J; Sobrevilla A; Rosales ML; Ibáñez M; Ruiz D; Penny E; Londoño S
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):661-669. PubMed ID: 38584495
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands.
Gout-Zwart JJ; de Jong LA; Saptenno L; Postma MJ
Pharmacoecon Open; 2020 Jun; 4(2):321-330. PubMed ID: 31535305
[TBL] [Abstract][Full Text] [Related]
20. (NDMA) METFORMIN AND (NTTP) SITAGLIPTIN INDUCED CUTANEOUS MELANOMAS: LINKS TO NITROSOGENESIS, NITROSO-PHOTOCARCINOGENESIS, ONCOPHARMACOGENESIS AND THE METABOLIC REPROGRAMMING.
Tchernev G; Broshtilova V
Georgian Med News; 2024 Mar; (348):132-143. PubMed ID: 38807407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
